Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2020 Aug 23

PMID 32825059

Citations 5

Authors

Giovanni Pallio

Federica Mannino

Natasha Irrera

Ali H Eid

Francesco Squadrito

Alessandra Bitto

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is a systemic disease that leads to joint destruction. During the last decade, the therapy of RA has been principally based on biological drugs. Although the efficacy of biological therapy has been established, patients demonstrated a high heterogeneity in clinical response to treatment. Several genetic polymorphisms play a part in the different response to biological drugs. This review summarizes the pharmacogenetics of biological agents approved for clinical RA treatment. We reviewed PubMed papers published over the past 20 years (2000-2020), inserting as the search term "rheumatoid arthritis and polymorphisms". Despite some studies showing important correlations between genetic polymorphisms and response to biological therapy in RA patients, most of these findings are still lacking and inconsistent. The personalized treatment according to a pharmacogenetics approach is promising but the available pharmacogenetics data on biological treatment in RA are not adequate and reliable to recommend pharmacogenetic tests before starting biological therapy in RA patients.

Citing Articles

Association of tumor necrosis factor-alpha promoter region gene polymorphism at positions -308G/A, -857C/T, and -863C/A with etanercept response in Iraqi rheumatoid arthritis patients.

Mohammed S, Zalzala M, Gorial F Arch Rheumatol. 2023; 37(4):613-625.

PMID: 36879565 PMC: 9985381. DOI: 10.46497/ArchRheumatol.2022.9272.

miRNA-Mediated Epigenetic Regulation of Treatment Response in RA Patients-A Systematic Review.

Mucientes A, Lisbona J, Mena-Vazquez N, Ruiz-Limon P, Manrique-Arija S, Fernandez-Nebro A Int J Mol Sci. 2022; 23(21).

PMID: 36361779 PMC: 9657910. DOI: 10.3390/ijms232112989.

Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis.

Lim S, Kim K, Choi C J Pers Med. 2022; 12(8).

PMID: 36013214 PMC: 9410311. DOI: 10.3390/jpm12081265.

Genetic and Clinical Factors Associated with Olokizumab Treatment in Russian Patients with Rheumatoid Arthritis.

Mikhaylenko D, Kuznetsova E, Musatova V, Bure I, Deryagina T, Alekseeva E J Pers Med. 2022; 12(4).

PMID: 35455757 PMC: 9024465. DOI: 10.3390/jpm12040641.

Latin American Genes: The Great Forgotten in Rheumatoid Arthritis.

Diaz-Pena R, Quinones L, Castro-Santos P, Duran J, Lucia A J Pers Med. 2020; 10(4).

PMID: 33114702 PMC: 7711650. DOI: 10.3390/jpm10040196.

References

Chen W, Xu H, Wang X, Gu J, Xiong H, Shi Y . The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis. Int Immunopharmacol. 2015; 28(1):146-53. DOI: 10.1016/j.intimp.2015.05.049. View

Pavy S, Toonen E, Miceli-Richard C, Barrera P, van Riel P, Criswell L . Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis. 2009; 69(6):1022-8. DOI: 10.1136/ard.2009.117622. View

Maxwell J, Potter C, Hyrich K, Barton A, Worthington J, Isaacs J . Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet. 2008; 17(22):3532-8. DOI: 10.1093/hmg/ddn245. View

Panoulas V, Stavropoulos-Kalinoglou A, Metsios G, Smith J, Milionis H, Douglas K . Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis. 2008; 204(1):178-83. DOI: 10.1016/j.atherosclerosis.2008.08.036. View

Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A . The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev. 2010; 11(5):315-20. DOI: 10.1016/j.autrev.2010.06.012. View

Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri F . Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis?. Rheumatol Int. 2008; 28(9):901-8. DOI: 10.1007/s00296-008-0552-5. View

Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M . Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust. 2006; 185(9):501-6. DOI: 10.5694/j.1326-5377.2006.tb00665.x. View

Jancic I, Sefik-Bukilica M, Zivojinovic S, Damjanov N, Spasovski V, Kotur N . Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis. J Med Biochem. 2017; 34(4):414-421. PMC: 4922353. DOI: 10.2478/jomb-2014-0060. View

ORielly D, Roslin N, Beyene J, Pope A, Rahman P . TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009; 9(3):161-7. DOI: 10.1038/tpj.2009.7. View

10.

Ruyssen-Witrand A, Rouanet S, Combe B, Dougados M, Le Loet X, Sibilia J . Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2012; 71(6):875-7. DOI: 10.1136/annrheumdis-2011-200337. View

11.

Davila-Fajardo C, Marquez A, Pascual-Salcedo D, Ramos M, Garcia-Portales R, Magro C . Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Pharmacogenet Genomics. 2013; 24(1):1-5. DOI: 10.1097/FPC.0000000000000013. View

12.

Seitz M, Wirthmuller U, Moller B, Villiger P . The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2006; 46(1):93-6. DOI: 10.1093/rheumatology/kel175. View

13.

Lee Y, Bae S, Song G . Functional FCGR3A 158 V/F and IL-6 -174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2014; 34(10):1409-15. DOI: 10.1007/s00296-014-3015-1. View

14.

Fonseca J, Carvalho T, Cruz M, Nero P, Sobral M, Mourao A . Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis. 2005; 64(5):793-4. PMC: 1755496. DOI: 10.1136/ard.2004.028167. View

15.

Zeng Z, Duan Z, Zhang T, Wang S, Li G, Gao J . Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis. Mod Rheumatol. 2012; 23(3):489-95. DOI: 10.1007/s10165-012-0699-5. View

16.

Gudbrandsdottir S, Larsen R, Sorensen L, Nielsen S, Hansen M, Svenson M . TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004; 22(1):118-24. View

17.

Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D . Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 2007; 57(8):1426-30. DOI: 10.1002/art.23092. View

18.

Enevold C, Baslund B, Linde L, Josephsen N, Tarp U, Lindegaard H . Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014; 24(8):401-5. DOI: 10.1097/FPC.0000000000000071. View

19.

Lee Y, Rho Y, Choi S, Ji J, Song G . Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int. 2006; 27(2):157-61. DOI: 10.1007/s00296-006-0175-7. View

20.

Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D . Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2007; 35(6):435-40. DOI: 10.1080/03009740600904284. View